Non-muscle Invasive Bladder Cancer Clinical Trial
Official title:
A Phase Ib/II Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-muscle Invasive Bladder Cancer
Verified date | January 2017 |
Source | Altor Bioscience Corporation |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a Phase Ib/II, open-label, multi-center and competitive enrollment study of ALT-801 combined with gemcitabine for patients who have BCG failure (defined as refractory, relapsing or intolerant), non-muscle invasive bladder cancer and refuse or are not medically fit to undergo a radical cystectomy recommended by the participating urologist as the standard next therapy per urologic guidelines. The purpose of this study is to confirm the safety and tolerability of a well-tolerated dose level of ALT-801, to determine the Recommended Dose level (RD) and characterize the immunogenicity of ALT-801 combined with gemcitabine in treated patients. The anti-tumor responses will also be assessed.
Status | Active, not recruiting |
Enrollment | 52 |
Est. completion date | March 2018 |
Est. primary completion date | April 2015 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
ENTRY CRITERIA: DISEASE CHARATERISTICS: - Histologically confirmed high-risk (high grade Ta, T1 or carcinoma in situ, tumor >4 cm or multi-focal) transitional cell carcinoma s/p TURBT with no remaining resectable disease within 4 weeks of study entry - Intolerant of treatment with BCG or failure (refractory or relapsing) of at least one prior treatment with BCG - Refuse or intolerant of a radical cystectomy - No Evidence of regional and/or distant metastasis PRIOR/CONCURRENT THERAPY: - No concurrent radiotherapy, other chemotherapy, or other immunotherapy - No scheduled radiotherapy, chemotherapy, other immunotherapy, or surgery before the scheduled response evaluation - Must have recovered from side effects of prior treatments - No concurrent use of other investigational agents PATIENT CHARACTERISTICS: Age • = 18 years Performance Status • ECOG 0, 1, or 2 Bone Marrow Reserve - Absolute neutrophil count (AGC/ANC) = 1,000/uL - Platelets = 100,000/uL - Hemoglobin = 8 g/dL Renal Function • Glomerular Filtration Rate (GFR) = 50mL/min Hepatic Function - Total bilirubin = 2.0 X ULN - AST, ALT, ALP = 3.0 X ULN Cardiovascular - No congestive heart failure < 6 months - No severe/unstable angina pectoris < 6 months - No myocardial infarction < 6 months - No history of ventricular arrhythmias - No NYHA Class > II CHF - No uncontrollable supraventricular arrhythmias - No history of a ventricular arrhythmia - No other clinical signs of severe cardiac dysfunction - Normal Transthoracic Echocardiogram (TTE) is required for patients who have history of EKG abnormalities, CHF, coronary artery disease or other cardiac disease, or have history of having received adriamycin or doxorubicin - No patients with a left ventricular ejection fraction (LVEF) of less than 50% Pulmonary • Normal clinical assessment of pulmonary function Other - Negative serum pregnancy test if female and of childbearing potential - Women who are not pregnant or nursing - Subjects, both females and males, with reproductive potential must agree to use effective contraceptive measures for the duration of the study - No known autoimmune disease other than corrected hypothyroidism - No known prior organ allograft or allogeneic transplantation - Not HIV positive - No active systemic infection requiring parenteral antibiotic therapy - No ongoing systemic steroid therapy required - No history or evidence of uncontrollable CNS disease - No psychiatric illness/social situation - No other illness that in the opinion of the investigator would exclude the subject from participating in the study - Must provide informed consent and HIPAA authorization and agree to comply with all protocol-specified procedures and follow-up evaluations |
Country | Name | City | State |
---|---|---|---|
United States | University of Alabama Comprehensive Cancer Center | Birmingham | Alabama |
United States | University of Oklahoma Health Science Center | Oklahoma City | Oklahoma |
United States | UF Health Center at Orlando Health | Orlando | Florida |
United States | UPMC Cancer Center | Pittsburgh | Pennsylvania |
United States | University of California Davis | Sacramento | California |
Lead Sponsor | Collaborator |
---|---|
Altor Bioscience Corporation | James and Esther King Biomedical Research Program |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety Profile | For Phase Ib & II Number and severity of treatment related AEs that occur or worsen after the first dose of study treatment |
12 weeks | |
Primary | Tolerability of ALT-801 combined with gemcitabine and designation of the Recommended Dose level (RD) | For phase Ib only Tolerability of a well-tolerated dose level of ALT-801 combined with gemcitabine and designation of the recommended dose level (RD) |
12 weeks | |
Primary | Clinical Benefit | For Phase Ib & II Number of participants with a complete response |
up to 13 weeks | |
Secondary | Duration of response | For Phase Ib & II All responding patients will be followed every 3 months during years 1 and 2 and every 6 month during year 3 to determine their duration of response |
up to 3 years | |
Secondary | Progression-free survival | For Phase Ib & II All patients receiving one complete dose of ALT-801 will be followed every 3 months during years 1 and 2 and every 6 month during year 3 to determine their progression-free survival |
up to 3 years | |
Secondary | Event free survival | For Phase Ib & II All patients receiving one complete dose of ALT-801 will be followed every 3 months during years 1 and 2 and every 6 month during year 3 to determine their event-free survival |
up to 3 years | |
Secondary | Overall survival | For Phase Ib & II All patients receiving one complete dose of ALT-801 will be followed every 3 months during years 1 and 2 and every 6 month during year 3 to determine their overall survival |
up to 3 years | |
Secondary | Immunogenicity of ALT-801 | For Phase Ib & II Measures the anti-ALT-801 and IL-2 neutralizing effects |
8 weeks | |
Secondary | Tumor Typing | For Phase Ib & II Assess the relationship between the tumor presentation of HLA-A*0201/p53 aa 264-272 complexes and the safety, immune response and clinical benefit of study treatment |
1 month |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04736394 -
A Phase 3 Study to Evaluate the Safety and Efficacy of APL-1202 as a Single-agent Oral Treatment Versus Intravesical Instillation of Epirubicin Hydrochloride in naïve Intermediate-risk NMIBC Patients
|
Phase 3 | |
Recruiting |
NCT05951179 -
Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
|
Phase 2 | |
Active, not recruiting |
NCT04943094 -
Clinical and Functional Consequences of Photodynamic Diagnosis (PDD) and Intravesical Instillation Therapy
|
||
Not yet recruiting |
NCT06227065 -
Precise Neoadjuvant Chemoresection of Low Grade NMIBC
|
Phase 2 | |
Completed |
NCT02969109 -
Validation of a Urine-based Assay With Genomic Markers for Predicting Recurrence for Non-muscle Invasive Bladder Cancer
|
||
Completed |
NCT01458847 -
Cis-urocanic Acid (Cis-UCA) in Patients With Primary or Recurrent Non-muscle Invasive Bladder Cancer
|
Phase 1 | |
Recruiting |
NCT03914794 -
A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors
|
Phase 2 | |
Recruiting |
NCT05126472 -
Study of 2141-V11 in People With Non-muscle Invasive Bladder Cancer That Did Not Respond to Standard Treatment
|
Phase 1 | |
Recruiting |
NCT04644835 -
Low Energy Shock Wave Therapy and Non-Muscle Invasive Bladder Cancer
|
N/A | |
Recruiting |
NCT06126796 -
Urine-based Molecular Testing vs Cystoscopy for Surveillance of Nonmuscle Invasive Bladder Cancer (NMIBC)
|
||
Active, not recruiting |
NCT04100733 -
Surveillance of High-grade Non-muscle Invasive Bladder Tumours Using the Xpert Bladder Cancer Monitor
|
N/A | |
Recruiting |
NCT05085990 -
Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
|
Phase 1 | |
Recruiting |
NCT03560479 -
A First-in-Human Study of alpha1H in Patients With Non-muscle Invasive Bladder Cancer
|
Phase 1/Phase 2 | |
Terminated |
NCT01310803 -
Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder
|
Phase 3 | |
Completed |
NCT03081858 -
Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT04498702 -
Study of Continuous APL-1202 Treatment in Subjects With High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Relapsed From Intravesical Chemo/BCG Therapy
|
Phase 2 | |
Recruiting |
NCT05337397 -
Outpatient Laser Ablation of Recurrent Non-muscle Invasive Bladder Cancer
|
||
Active, not recruiting |
NCT04490993 -
Safety and Efficacy of APL-1202 in Combination With Epirubicin Hydrochloride Versus Epirubicin Hydrochloride Alone in Intermediate and High-risk Chemo-refractory Non-muscle Invasive Bladder Cancer (NMIBC) Patients
|
Phase 3 | |
Recruiting |
NCT04859751 -
Study of VB4-845 Injection for Treating Patients With Non-muscle Invasive Bladder Cancer
|
Phase 3 | |
Recruiting |
NCT05672615 -
Mood Alterations in the Patients With Non-Muscle Invasive Bladder Cancer Treated With BCG
|